West Midlands research study reveals attitudes to vaccines
A recent survey undertaken by the University of Birmingham is among the first cross-sectional survey to examine factors influencing COVID-19 vaccine hesitancy.
A recent survey undertaken by the University of Birmingham is among the first cross-sectional survey to examine factors influencing COVID-19 vaccine hesitancy.

The study was carried out by researchers from the Universities of Birmingham and Wolverhampton
A recent survey undertaken by Dr Anandadeep Mandal (Birmingham Business School) and Professor Paul Moss, Deputy Head of College of Medical and Dental Sciences, hopes to influence government policy on vaccine hesitancy.
It is believed to be the largest and first cross-sectional survey in the UK to examine the various factors influencing the uptake of a potential approved COVID-19 vaccine. On Tuesday 8 December, the UK became the first official country to roll out a national COVID-19 vaccine programme, so these results are timely.
'The Uptake Study: Insights And Beliefs Of The UK Population On Vaccines During The COVID-19 Pandemic' was carried out by researchers from the Universities of Birmingham and Wolverhampton with the support of the NIHR, Clinical Research Network West Midlands (CRN WM) and The Royal Wolverhampton NHS Trust (RWT).
This study is currently only available in a pre-print version and awaits submission and formal peer-review.
The data however, provide a unique insight into the key drivers and barriers to vaccine uptake from the largest UK survey to date. 4,884 people responded to the invitation to the survey between 4 September 2020 and 9 October 2020.
Key findings were:
It’s also believed to be the first study to identify smokers as being less likely to accept approved vaccines which could be an area of concern. However, it gives reassurance that the high-risk groups identified by the UK government are more likely to take the vaccine.
This is the largest COVID-19 vaccine uptake study in the UK that has explored the key drivers and barriers to COVID-19 vaccine acceptance at a pivotal time, when Pfizer’s Phase 3 trials has just reported promising results. This study provides valuable insights in supporting and promoting uptake in a subsequent population-wide vaccine programme.
This study was among the top ten most downloaded papers for SSRN LANCET as of 1 January 2021. The results of this study were shared with the UK governments Vaccine Task Force in November 2020.

Associate Professor in Finance
Dr Anandadeep Mandal's primary research interest is in the field of quantitative finance.

Deputy Head of College of Medicine and Health
Professor Moss is Professor of Haematology at the University of Birmingham and Deputy Head of the College of Medicine and Health. He is an NIHR Senior Investigator.